Hot Topics in Cardiology - Editors-in-chief: Sergio Dalla Volta, Christopher P. Cannon
Use these Web pages for faster access to state-of the-art medical topics in various specialties to keep abreast of practical clinical information and research results.
Tuesday, 07 September 2010
You are here: Hot Topics in Cardiology - Editors-in-chief: Sergio Dalla Volta, Christopher P. Cannon
HOT TOPICS IN CARDIOLOGY: Issue 5, 2007
Angiotensin AT1 receptor antagonists in patients at high risk for cardiovascular events: the state of the art
Angiotensin AT1 receptor antagonists in patients at high risk for cardiovascular events: the state of the art
Angiotensin AT1 receptor antagonists in patients at high risk for cardiovascular events: the state of the art
Thomas Unger, Jan H. Schefe
Correspondence to:
Thomas Unger - M.D.
Professor of Pharmacology
Center for Cardiovascular Research (CCR)/ Institute of Pharmacology
Charité - Universitätsmedizin Berlin
Campus Charité-Mitte
Berlin, Germany
E-mail: thomas.unger@charite.de
Thomas Unger - M.D.
Professor of Pharmacology
Center for Cardiovascular Research (CCR)/ Institute of Pharmacology
Charité - Universitätsmedizin Berlin
Campus Charité-Mitte
Berlin, Germany
E-mail: thomas.unger@charite.de
Summary
- THE RENIN-ANGIOTENSIN SYSTEM: GENERAL ASPECTS
- Biochemistry of the renin-angiotensin system
- Angiotensinogen
- Renin
- Angiotensin-converting enzyme
- Angiotensin receptors
- Renin receptor
- PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL ASPECTS OF THE RENIN-ANGIOTENSIN SYSTEM
- Angiotensin-mediated effects
- Vasoconstriction and blood pressure
- Sodium retention
- Proliferation and apoptosis
- Angiotensin II effects in different organs
- Heart
- Brain
- Kidney
- Vascular wall
- Physiological and pathophysiological aspects of the angiotensin receptors
- PHARMACOLOGY OF ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS
- General pharmacological aspects
- Adverse effects and contraindications
- Differences between angiotensin AT1 receptor antagonists
- ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS AND HYPERTENSION
- Clinical trials
- LIFE
- SCOPE
- VALUE
- Ongoing clinical trials
- Conclusion
- ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS IN CHRONIC HEART FAILURE
- Clinical trials
- CHARM-alternative
- CHARM-preserved
- CHARM-added
- RESOLVD
- Val-HeFT
- ELITE and ELITE-II
- Conclusion
- ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS IN ACUTE AND POST-ACUTE MYOCARDIAL INFARCTION
- Clinical trials
- OPTIMAAL
- VALIANT
- Conclusion
- ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS IN CEREBRAL STROKE
- Clinical trials
- Conclusion
- ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS IN DIABETES AND METABOLIC SYNDROME
- Clinical trials
- Mechanisms
- Conclusion
- ANGIOTENSIN AT1 RECEPTOR ANTAGONISTS IN PATIENTS AT HIGH CARDIOVASCULAR RISK
- CONCLUSION
- REFERENCES
